Bank of Montreal Can Buys 18,532 Shares of Hologic, Inc. (NASDAQ:HOLX)

Bank of Montreal Can increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 492,210 shares of the medical equipment provider’s stock after purchasing an additional 18,532 shares during the quarter. Bank of Montreal Can’s holdings in Hologic were worth $39,780,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Cetera Investment Advisers increased its position in shares of Hologic by 188.9% during the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after purchasing an additional 13,380 shares during the last quarter. Andra AP fonden boosted its holdings in Hologic by 224.5% during the 2nd quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock valued at $7,083,000 after acquiring an additional 66,000 shares during the period. Swedbank AB boosted its holdings in Hologic by 5.2% during the 2nd quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock valued at $121,060,000 after acquiring an additional 80,575 shares during the period. GAMMA Investing LLC boosted its holdings in Hologic by 17.9% during the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after acquiring an additional 582 shares during the period. Finally, Comerica Bank boosted its holdings in Hologic by 40.9% during the 1st quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock valued at $8,580,000 after acquiring an additional 31,967 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.6 %

Shares of NASDAQ HOLX opened at $79.44 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock has a market capitalization of $18.45 billion, a P/E ratio of 23.86, a price-to-earnings-growth ratio of 2.51 and a beta of 0.98. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The business has a fifty day moving average price of $80.28 and a 200 day moving average price of $78.42.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.89 EPS. Equities research analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HOLX. Royal Bank of Canada boosted their price objective on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Raymond James boosted their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Leerink Partners lowered their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.